Insights - GW Pharma (GWPH) announced the submission of its rolling NDA for their cannabidiol candidate Epidiolex, treating rare epilepsy conditions Lennox-Gastaut Syndrome and Dravet Syndrome. At … Continue Reading
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.